217 related articles for article (PubMed ID: 34082809)
1. Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer.
Nakanishi S; Goya M; Tamaki M; Oshiro T; Saito S
BMC Res Notes; 2021 Jun; 14(1):227. PubMed ID: 34082809
[TBL] [Abstract][Full Text] [Related]
2. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.
Miyoshi Y; Yoneyama S; Kawahara T; Hattori Y; Teranishi JI; Ohta JI; Takebayashi S; Yokomizo Y; Hayashi N; Uemura H
Urol Int; 2017; 99(4):400-405. PubMed ID: 28609769
[TBL] [Abstract][Full Text] [Related]
4. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
[TBL] [Abstract][Full Text] [Related]
5. [Risk factors for early castration-resistant prostate cancer after androgen deprivation therapy for bone-metastatic prostate cancer].
Huang FM; Li XH; Liang Y
Zhonghua Nan Ke Xue; 2018 Aug; 24(8):690-694. PubMed ID: 30173426
[TBL] [Abstract][Full Text] [Related]
6. Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study.
Ji G; Song G; Huang C; He S; Zhou L
Medicine (Baltimore); 2017 Sep; 96(36):e7823. PubMed ID: 28885333
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.
Kim M; Lee J; Jeong CW; Ku JH; Kim HH; Kwak C
Urol Oncol; 2015 May; 33(5):203.e1-9. PubMed ID: 25726498
[TBL] [Abstract][Full Text] [Related]
8. Retrospective validation of bone risk stratification criteria for men with de novo metastatic hormone-naive prostate cancer in China.
Zhang Y; Ding L; Zheng Y; Wang K; Xia W; Wang J; Ge P
PeerJ; 2023; 11():e14500. PubMed ID: 36624752
[TBL] [Abstract][Full Text] [Related]
9. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
[TBL] [Abstract][Full Text] [Related]
10. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
[TBL] [Abstract][Full Text] [Related]
11. Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer.
Tsuzuki S; Kawano S; Fukuokaya W; Mori K; Nishikawa H; Tashiro K; Watanabe D; Uchimoto T; Nishimura K; Yano Y; Murakami M; Koike Y; Hata K; Koide H; Miki J; Abe H; Yamada H; Naruoka T; Sugaya S; Kimura T; Tomita M; Nakajo H; Egawa S
Jpn J Clin Oncol; 2021 Nov; 51(11):1665-1671. PubMed ID: 34296282
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
13. Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer.
Hamano I; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
World J Urol; 2019 Nov; 37(11):2365-2373. PubMed ID: 30729312
[TBL] [Abstract][Full Text] [Related]
14. Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.
Nakabayashi M; Hayes J; Taplin ME; Lefebvre P; Lafeuille MH; Pomerantz M; Sweeney C; Duh MS; Kantoff PW
Cancer; 2013 Aug; 119(16):2990-8. PubMed ID: 23719969
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice.
Park K; Kim JY; Park I; Shin SH; Lee HJ; Lee JL
Yonsei Med J; 2023 Feb; 64(2):86-93. PubMed ID: 36719015
[TBL] [Abstract][Full Text] [Related]
16. Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer.
Sato H; Narita S; Tsuchiya N; Koizumi A; Nara T; Kanda S; Numakura K; Tsuruta H; Maeno A; Saito M; Inoue T; Satoh S; Nomura K; Habuchi T
BMC Urol; 2018 May; 18(1):32. PubMed ID: 29739368
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan.
Narita S; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Koizumi A; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nomura K; Habuchi T
Int J Clin Oncol; 2020 May; 25(5):912-920. PubMed ID: 31919691
[TBL] [Abstract][Full Text] [Related]
18. Treatment strategy for metastatic prostate cancer with extremely high PSA level: reconsidering the value of vintage therapy.
Yamada Y; Sakamoto S; Amiya Y; Sasaki M; Shima T; Komiya A; Suzuki N; Akakura K; Ichikawa T; Nakatsu H
Asian J Androl; 2018; 20(5):432-437. PubMed ID: 29735818
[TBL] [Abstract][Full Text] [Related]
19. Periprostatic Fat Thickness on MRI is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Chinese Patients With Newly Diagnosed Prostate Cancer Treated With Androgen Deprivation Therapy.
Huang H; Chen S; Li W; Bai P; Wu X; Xing J
Clin Genitourin Cancer; 2019 Oct; 17(5):e1036-e1047. PubMed ID: 31281063
[TBL] [Abstract][Full Text] [Related]
20. Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer.
Kodama H; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Narita T; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
Clin Genitourin Cancer; 2019 Dec; 17(6):e1091-e1098. PubMed ID: 31575477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
